The clinical trial of Calcitonin Gene-Related Peptide was started

Photo by Nik Shuliahin

Danish Headache Center (DHC) is commencing recruitment for the clinical trial of hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab.

The leading headache center aims to explore the relationship between clinical response to erenumab and response to intravenous infusion of calcitonin gene-related peptide in individuals with migraine.

This is a single-center, non-randomized, single-arm, open-label study, in which adults with episodic or chronic migraine will receive intravenous infusion with calcitonin gene-related peptide and subsequently be treated with erenumab.

DHC plans to complete the clinical trial by August 1, 2025.

Patients may be involved in the study according to the requirements described below:

  • age of 18 or older upon entry into screening;
  • history of migraine with or without aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria;
  • 4 headache days that meet criteria as migraine days per month on average across the 3 months before screening.

Danish Headache Center (Copenhagen, Glostrup, Denmark, 2600) is the recruitment facility.

The Danish Headache Center is one of the leading headache centers in the world. DHC offers highly specialized and multidisciplinary treatment of severe and rare headaches and facial pain disorders. Additionally, DHC is involved in advanced research covering preclinical experimental in vitro and in vivo models as well as experimental human headache models, human genetics and epidemiology and development of new treatment approaches.

For more details please follow the link:

Clinical Research News

Upcoming Clinical Trials